A Phase IB/II Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab to Treat Recurrent or Persistent T-Cell Lymphoma

Share
Print

Full Title

A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma (NCI 10384) (CIRB)

Purpose

The purpose of this study is to determine the highest dose of the investigational drug Hu5F9-G4 (magrolimab) that can be given safely in combination with mogamulizumab in patients with cutaneous T-cell lymphoma (mycosis fungoides or Sézary disease) that has come back after or stopped responding to treatment. Mogamulizumab is already used to treat T-cell lymphoma. Hu5F9-G4 works against cancer by inhibiting CD47, a protein involved in the growth of some cancer cells. Giving Hu5F9-G4 with mogamulizumab could boost the effectiveness of treatment. Both medications are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have mycosis fungoides or Sézary disease that came back or continued to grow despite treatment.
  • At least 3 weeks must pass since the completion of prior anticancer medications, 2 weeks since radiation therapy and topical therapies, and 12 weeks for total skin electron beam therapy and receipt of the study treatment. Prior treatment with mogamulizumab is not permitted.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Steven Horwitz at 646-608-3725.

Protocol

21-128

Phase

I/II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators